ESMO 2019 | MONALEESA-3 OS results: fulvestrant/ribociclib in postmenopausal HR+/HER2- advanced breast cancer

Dennis Slamon, MD, PhD, of David Geffen School of Medicine at UCLA, Los Angeles, CA, presents the overall survival results from the phase 3 MONALEESA-3 trial (NCT02422615). This trial analyzed fulvestrant with or without ribociclib in postmenopausal patients HR+/HER2- advanced breast cancer. Following this, Nadia Harbeck, MD, PhD, from Ludwig Maximilian University of Munich, Munich, Germany, gives her insight into the results presented for MONALEESA-3 and MONARCH 2.